整理 | GLP1减重宝典内容团队 胰高血糖素样肽-1 受体激动剂(GLP-1 RA) 药物的兴起改变了医疗保健格局，引起了广泛关注和采用。根据最近的 KFF 健康追踪调查， 美国八分之一的成年人服用过 GLP-1 RA 药物，突显了其惊人的受欢迎程度。 此外，Truveta的团队还显示GLP-1RA 处方量增加。 这 些药物最初是为治疗 2 型糖尿病而开发的，其适应症已扩大到肥胖症和心血管疾病，从而扩大了其吸引力和实用性。 Truveta想知道这些药物如何在治疗模式中发挥作用，特别是在超重或肥胖人群中。变化的求医行为是否会促使首次诊断的增加或改变患 者与医疗保健系统的互动方式？Truveta与路透社独家合作， 以更好地了解首次 GLP-1 RA 处方后 15 天内患者的首次诊断模 式，并了 解这种情况可能如何随时间发生变化 。 点击关注，追踪最新GLP-1资讯 ▍研究方法 ▍首次处方率 下表显示了首次服用 GLP-1 处方后15 天内首次诊断为 2 型糖尿病、心血管疾病或睡眠呼吸暂停的人群百分比。随着 2 型糖尿病和睡眠 呼吸暂停的超重/肥胖等级的增加，首次诊断率也随之增加。 | | T2D | CVD | ...

以上内容基于公开资料整理，不构成投资建议。 股票近期走势截至2026年2月13日收盘，银诺医药-B股价报27.60港元，近5个交易日累计上涨2.83%，但 近20个交易日下跌10.91%。南向资金近期呈现波动，2月10日单日减持20.14万股，近5个交易日累计净 减持85.2万股，不过近20个交易日整体净增持168.1万股，当前持有306.08万股，占已发行普通股 0.72%。2月13日资金流向显示总净流入529,140港元，散户资金活跃。 经济观察网2026年2月4日，银诺医药宣布其核心产品依苏帕格鲁肽α用于治疗宠物糖尿病的新兽药临床 试验申请获农业农村部受理，预计2026年第一季度启动I期临床试验。该消息于2026年2月7日由知宠分 子报道，股价在2月5日出现显著上涨。此外，2026年2月6日，公司公告联席公司秘书变更，金今女士因 个人原因辞任，杨东妍女士获委任为新联席秘书。 ...

Core Viewpoint - The competition for GLP-1 weight loss drugs in China by 2026 will shift from who can get approved first to who can survive under pressure from payment and distribution channels while continuing to grow [4] Group 1: Market Dynamics - In 2025, the market will see a competitive landscape where Novo Nordisk's semaglutide system dominates, Eli Lilly's tirzepatide penetrates the market, and domestic players like Innovent and Yinoo differentiate themselves with dual-target GLP-1/GCG and long-acting GLP-1 products [6] - By 2026, the market will face intensified competition as insurance pricing pressures increase, major players normalize price wars, and the patent for semaglutide approaches expiration, leading to a surge in supply from biosimilars and similar products [6][9] Group 2: Company Strategies - For Novo Nordisk, the key challenge in 2025 is not new drug approvals but the rare decline in core products in Greater China, necessitating aggressive pricing and channel policies to maintain market share [7] - Eli Lilly's strategy involves a dual approach: using insurance pricing to gain scale in hospitals while adopting flexible retail strategies to capture weight management users [7] - Domestic companies face a common challenge of needing to reassess revenue models as major players drive prices down and insurance anchors lower, making it difficult to sustain high pricing and growth expectations [9] Group 3: New Variables in 2026 - The introduction of oral small-molecule GLP-1s will significantly increase competition in outpatient settings, with Eli Lilly's Orforglipron expected to enhance long-term adherence and channel integration [10] - The impact of insurance and hospital procurement will be felt in 2026, with products entering insurance quickly expanding prescription volumes but requiring acceptance of lower payment prices [10] - The market will see a surge of new domestic players, including those with recently approved products and innovative candidates that could disrupt the market structure [11][12] Group 4: Price Structure and Market Segmentation - By late 2026, the GLP-1 market in China will likely form a three-tier structure: a premium tier for original and strong innovative brands, a second tier for domestic innovations, and a third tier for biosimilars and similar products competing on price [20] - The expiration of semaglutide's patent will lead to a significant shift in the pricing landscape, requiring companies to adopt more conservative revenue expectations and refined commercialization strategies to avoid price wars [21]

整理 | GLP1减重宝典内容团队 从人用到宠用，GLP-1 正在打开一个全新的蓝海。 2 月 4 日，银诺医药发布公告称，其核心产品依苏帕格鲁肽 α用于治疗宠物糖尿病的新兽药临床试验申请，已正式获得农业农村部受理，预计 将于 2026 年第一季度启动 I 期临床试验。这意味着，GLP-1 这一近年席卷人类代谢疾病市场的明星机制，正加速向宠物医疗领域渗透。 从技术层面看，依苏帕格鲁肽 α 并非"简单移植"的人用药。该产品属于新一代人源超长效 GLP-1 融合蛋白，通过基因工程重组蛋白技术，在 GLP-1 与 IgG2 之间引入独特的天然铰链结构，形成稳定的双分子构型。这一设计显著增强了其对 GLP-1 受体的亲和力，同时大幅降低了体内 酶降解与肾脏滤过速度。在成人 2 型糖尿病患者中，该药物已验证平均半衰期可达 204 小时，支持 1–2 周一次皮下注射，在疗效与依从性之间 取得平衡——这恰恰是宠物长期慢病管理中最稀缺的特性。 在人用市场，依苏帕格鲁肽 α 的商业路径已初步跑通。2025 年 1 月，该产品在国内获批上市，用于成人 2 型糖尿病治疗，既可单药使用，也 适用于在二甲双胍基础上血糖控制不佳的人群， ...

2月5日A股收盘后，港股迎来直线拉升行情。恒生指数实现转涨，恒生科技指数涨近1%。此前一度跌超3%的腾讯控股随后翻红，市场此前流传的调整游 戏、金融等行业增值税税率的传言引发的担忧正逐步消退。 当日早间，百度集团-SW发布公告，宣布授权实施一项新的股票回购计划，最高回购金额为50亿美元，有效期至2028年12月31日。同时，为进一步提升股东 回报，董事会已批准首次采纳股息政策，预计2026年宣布首次派发股息。受上述消息推动，百度集团-SW拉升逾3%。 港股新能源汽车板块尾盘同步拉升，蔚来、小米集团涨超3%，零跑汽车、理想汽车、比亚迪股份、小鹏汽车等个股跟涨。 银诺医药-B早盘拉升逾17%，消息面显示，公司核心产品依苏帕格鲁肽α用于治疗宠物糖尿病的新兽药临床试验申请已于2月4日获农业农村部正式受理，预 计2026年第一季度启动I期临床试验。董事会表示，宠物糖尿病药物研发具备广阔前景，符合集团长期业务发展策略，将为集团进军宠物药品领域奠定坚实 基础。 市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 ...

2月5日，银诺医药(2591.HK)新兽药临床试验申请获农业部受理，刺激股价上升，盘中一度飙升20%报 31港元。公司公布，核心产品依苏帕格鲁肽α用于治疗宠物糖尿病的新兽药临床试验申请获中国农业农 村部正式受理。预计将于今年第一季度开始I期临床试验。 董事会认为，研发宠物糖尿病药物具有广阔的前景。由于人们愈发愿意接受并花费金钱延长宠物的寿 命，董事会认为，此类研发符合集团的长期业务发展策略，并将为集团未来进军宠物药品领域奠定坚实 的基础。 港股频道更多独家策划、专家专栏，免费查阅>> 责任编辑：山上 ...

银诺医药(2591.HK)新兽药临床试验申请获农业部受理，刺激股价上升，盘中一度飙升20%报31港元。 公司公布，核心产品依苏帕格鲁肽α用于治疗宠物糖尿病的新兽药临床试验申请获中国农业农村部正式 受理。预计将于今年第一季度开始I期临床试验。 董事会认为，研发宠物糖尿病药物具有广阔的前景。由于人们愈发愿意接受并花费金钱延长宠物的寿 命，董事会认为，此类研发符合集团的长期业务发展策略，并将为集团未来进军宠物药品领域奠定坚实 的基础。 ...

Market Overview - The A-share market experienced a decline on February 5, with the ChiNext and STAR Market leading the drop, particularly in the non-ferrous metals sector, which saw a decline of over 5% [3] - The banking sector showed a rebound near the close, with gains exceeding 1% for several banks [5] Non-Ferrous Metals Sector - The non-ferrous metals sector faced significant losses, with stocks like Hunan Gold and Hunan Silver hitting the daily limit down [3] - Domestic metal futures fell across the board, with the main contract for silver futures dropping over 10% [3] - Spot gold prices decreased by 3% to $4,809.87 per ounce [3] Stock Performance - Notable declines were observed in various stocks, including Hunan Silver down by 9.97% and Sichuan Gold down by 9.07% [4] - The electric equipment sector also saw a decline of over 3%, with several stocks hitting the daily limit down [4] New Listings - A new stock, North Chip Life, saw a significant increase of over 210% during its debut, focusing on innovative solutions for cardiovascular diseases [7] - The company has launched 11 products and has 6 in development, including the first domestically approved IVUS diagnostic system [7] Hong Kong Market - The Hong Kong market also faced a downturn, with the Hang Seng Index dropping over 1% [8] - Yum China Holdings saw its stock price rise by over 9% following the release of its Q4 2025 financial results [10] Yum China Financial Performance - Yum China's Q4 2025 system sales increased by 7% year-on-year, with same-store sales up by 3%, marking the third consecutive quarter of growth [12] - The company added a record 587 new stores in Q4, with 36% being franchise stores, and operating profit rose by 25% to $187 million [12]

Market Overview - The A-share market experienced a decline today, with the ChiNext and Sci-Tech Innovation Board leading the drop, particularly in the non-ferrous metals sector which saw a significant plunge [1][5] - The Hong Kong market also faced a downturn, with the Hang Seng Index dropping over 1%, although Yum China saw its stock price surge by over 9% following the release of its financial results [3][12] Sector Performance - The non-ferrous metals sector faced a severe setback, with a drop exceeding 5% during the session. Key stocks such as Silver Industry and Hunan Gold hit their daily limit down [5][6] - Domestic metal futures experienced widespread declines, with the main contract for silver futures plummeting over 10%. Spot gold also fell by 3% to $4,809.87 per ounce [5] - The power equipment sector was among the worst performers, with a drop exceeding 3%, and several stocks, including Zhongheng Electric and Jinchen Co., hitting their daily limit down [7] - Other sectors such as coal, steel, and telecommunications also reported significant declines, while the beauty and personal care sector led the gains with an increase of over 3% [8] Notable Stock Movements - Yum China's stock price increased significantly, with a peak rise of over 9% after announcing a 7% year-on-year increase in system sales for Q4 2025, and a 3% increase in same-store sales [11][18] - A new stock, North Chip Life, debuted with a remarkable rise of over 210% during the session. The company focuses on innovative solutions for cardiovascular diseases and has several products in the pipeline [10][14] Financial Results - Yum China's Q4 2025 financial results showed a net increase of 587 new stores, with a 36% share of new franchise stores, and a 25% increase in operating profit to $187 million [18]

银诺医药-B(02591)早盘拉升逾17%，截至发稿，涨16.11%，报29.26港元，成交额1721.86万港元。 董事会认为，研发宠物糖尿病药物具有广阔的前景。由于人们愈发愿意接受并花费金钱延长宠物的寿 命，董事会认为，此类研发符合集团的长期业务发展策略，并将为集团未来进军宠物药品领域奠定坚实 的基础。 消息面上，银诺医药-B发布公告，于2026年2月4日，公司核心产品依苏帕格鲁肽α用于治疗宠物糖尿病 的新兽药临床试验申请已获中华人民共和国农业农村部正式受理。预计将于2026年第一季度开始I期临 床试验。 集团已遵守农业部规定的所有兽药研发与注册相关标准及监管规定，并已成功完成相关临床前试验。根 据临床前试验结果，就疗效和安全性而言，依苏帕格鲁肽α在宠物糖尿病管理方面已取得积极进展，可 为后续开展该药物相关的临床试验和注册申请提供合理依据。 ...